Dicerna Pharmaceuticals, Inc.
BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE
Last updated:
Abstract:
Provided herein is a potent, optimized .beta.-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides. Also provided are methods and compositions for reducing .beta.-catenin expression and methods and compositions for treating cancer.
Status:
Application
Type:
Utility
Filling date:
15 Apr 2021
Issue date:
5 Aug 2021